Quick Answer
Kairos Pharma, LTD. reported Net Income of -$5.45 million for fiscal year 2025.
Kairos Pharma, LTD. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$5.45M -109.3% |
-$2.60M -43.7% |
-$1.81M | — |
| Diluted EPS | -$0.30 -30.4% |
-$0.23 -35.3% |
-$0.17 | — |
| Total Assets | $6.54M +13.4% |
$5.77M +497.7% |
$965.0K | — |
| Cash and Equivalents | $4.49M +253.1% |
$1.27M | — | — |
| Stockholders Equity | $6.34M +32.8% |
$4.78M +329.8% |
-$2.08M -76.3% |
-$1.18M |
| R&D Expense | $2.13M +415.7% |
$414.0K +404.9% |
$82.0K | — |
| Operating Income | -$5.57M -137.8% |
-$2.34M -36.7% |
-$1.71M | — |
| Shares Outstanding | 20.82M +51.6% |
13.74M +30.0% |
10.56M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.40M | -33.5% | +1.7% |
| Diluted EPS | September 30, 2025 | -$0.07 | +30.0% | +12.5% |
| Total Assets | September 30, 2025 | $8.07M | +61.2% | +20.9% |
| Cash and Equivalents | September 30, 2025 | $5.58M | — | +83.8% |
| Stockholders Equity | September 30, 2025 | $7.66M | +130.0% | +27.8% |
| R&D Expense | September 30, 2025 | $608.0K | +4242.9% | +22.6% |
| Operating Income | September 30, 2025 | -$1.44M | -274.7% | +1.4% |
| Shares Outstanding | September 30, 2025 | 20.82M | +62.1% | +17.3% |
- Kairos Pharma, LTD. reported Net Income of -$5.45 million for fiscal year 2025.
- Kairos Pharma, LTD. showed a decrease of -109.3% in Net Income compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Diluted EPS of $0.30 per share (loss) for fiscal year 2025.
- Kairos Pharma, LTD. showed a decrease of -30.4% in Diluted EPS compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Total Assets of $6.54 million for fiscal year 2025.
- Kairos Pharma, LTD. showed an increase of +13.4% in Total Assets compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Cash and Equivalents of $4.49 million for fiscal year 2025.
- Kairos Pharma, LTD. showed an increase of +253.1% in Cash and Equivalents compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Stockholders Equity of $6.34 million for fiscal year 2025.
- Kairos Pharma, LTD. showed an increase of +32.8% in Stockholders Equity compared to the prior fiscal year.
- Kairos Pharma, LTD. reported R&D Expense of $2.13 million for fiscal year 2025.
- Kairos Pharma, LTD. showed an increase of +415.7% in R&D Expense compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Operating Income of -$5.57 million for fiscal year 2025.
- Kairos Pharma, LTD. showed a decrease of -137.8% in Operating Income compared to the prior fiscal year.
- Kairos Pharma, LTD. reported Shares Outstanding of 20.82 million shares for fiscal year 2025.
- Kairos Pharma, LTD. showed an increase of +51.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: